參考文獻
RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open label, platform trial. Lancet (London, England), 397(10285), 1637–1645.
REMAP-CAP Investigators, Gordon, A. C., Mouncey, P. R., Al-Beidh, F., Rowan, K. M., Nichol, A. D., Arabi, Y. M., Annane, D., Beane, A., van Bentum-Puijk, W., Berry, L. R., Bhimani, Z., Bonten, M., Bradbury, C. A., Brunkhorst, F. M., Buzgau, A., Cheng, A. C., Detry, M. A., Duffy, E. J., Estcourt, L. J., … Derde, L. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine, 384(16), 1491–1502.
Ghosn, L., Chaimani, A., Evrenoglou, T., Davidson, M., Graña, C., Schmucker, C., Bollig, C., Henschke, N., Sguassero, Y., Nejstgaard, C. H., Menon, S., Nguyen, T. V., Ferrand, G., Kapp, P., Riveros, C., Ávila, C., Devane, D., Meerpohl, J. J., Rada, G., Hróbjartsson, A., … Boutron, I. (2021). Interleukin-6 blocking agents for treating COVID-19: a living systematic review. The Cochrane database of systematic reviews, 3, CD013881.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., … ACTT-1 Study Group Members (2020). Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine, 383(19), 1813–1826.
WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A. M., Preziosi, M. P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M. M., Hernández García, C., Kieny, M. P., Malekzadeh, R., Murthy, S., Reddy, K. S., Roses 6 2021年09月∣第28卷第3期 www2.cch.org.tw/layout_5/index.aspx?id=5100 醫護論述 Periago, M., Abi Hanna, P., Ader, F., Al-Bader, A. M., Alhasawi, A., Allum, E., Alotaibi, A., … Swaminathan, S. (2021). Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England journal of medicine, 384(6), 497– 511.
延伸閱讀
- 張朔衽、張倩蜜、曾麗卿、趙岑恩、陳淑純、張艾玲、張淑真、李雅文（2022）。新冠肺炎（COVID-19）期間護理人力整備及應變計畫之成效。醫管新冠肺炎防疫專刊，()，70-83。https://doi.org/10.29636/SIHMCOVID-19P.202112_70
- 李淑英、陳國緯（2022）。新型冠狀病毒肺炎（COVID-19）與真菌感染之文獻回顧。疫情報導，38(9)，97-103。https://doi.org/10.6524/EB.202205_38(9).0001
- 馬聖翔、陳志強（2022）。新冠肺炎（COVID-19）感染的皮膚表現。臨床醫學月刊，90(5)，701-703。https://doi.org/10.6666/ClinMed.202211_90(5).0113
- 黃智瑋、王俊隆、賴致中、賴俊良（2021）。醫療資訊管理在新冠肺炎（COVID-19）防疫措施之運用。醫療品質雜誌，15(6)，82-86。https://doi.org/10.3966/199457952021111506015
- 田至峰、蔡宛庭、蔡瑋祥、余冠儀（2023）。新冠肺炎COVID-19藥物發展。感染控制雜誌，33(1)，51-55。https://doi.org/10.6526/ICJ.202302_33(1).0006